Australia - English - Department of Health (Therapeutic Goods Administration)

torrent australasia pty ltd - esomeprazole magnesium, quantity: 41.412 mg (equivalent: esomeprazole, qty 40 mg) - tablet, enteric coated - excipient ingredients: povidone; colloidal anhydrous silica; purified talc; silicified microcrystalline cellulose; light magnesium oxide; magnesium stearate; iron oxide red; diethyl phthalate; hypromellose; polysorbate 80; methacrylic acid - ethyl acrylate copolymer (1:1); sodium lauryl sulfate; ethylcellulose; titanium dioxide; macrogol 8000; crospovidone; copovidone; lactose monohydrate; maize starch; sucrose; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - gastro-oesophageal reflux disease (gord),? treatment of erosive reflux oesophagitis,? long-term management of patients with healed oesophagitis to prevent relapse,? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy,? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy.,? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy,? prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv (available in other brands) solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion,in combination with appropriate antibiotics for:,? healing of duodenal ulcer associated with helicobacter pylori,? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australia - English - Department of Health (Therapeutic Goods Administration)

torrent australasia pty ltd - esomeprazole magnesium, quantity: 20.706 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: hypromellose; light magnesium oxide; povidone; colloidal anhydrous silica; polysorbate 80; iron oxide red; crospovidone; silicified microcrystalline cellulose; methacrylic acid - ethyl acrylate copolymer (1:1); magnesium stearate; macrogol 8000; purified talc; ethylcellulose; copovidone; titanium dioxide; diethyl phthalate; sodium lauryl sulfate; lactose monohydrate; maize starch; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid; sucrose - gastro-oesophageal reflux disease (gord),? treatment of erosive reflux oesophagitis,? long-term management of patients with healed oesophagitis to prevent relapse,? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy,? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy.,? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy,? prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv (available in other brands) solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion,in combination with appropriate antibiotics for:,? healing of duodenal ulcer associated with helicobacter pylori,? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australia - English - Department of Health (Therapeutic Goods Administration)

torrent australasia pty ltd - esomeprazole magnesium, quantity: 20.706 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: copovidone; titanium dioxide; hypromellose; polysorbate 80; crospovidone; silicified microcrystalline cellulose; light magnesium oxide; colloidal anhydrous silica; povidone; diethyl phthalate; methacrylic acid - ethyl acrylate copolymer (1:1); magnesium stearate; ethylcellulose; macrogol 8000; iron oxide red; sodium lauryl sulfate; purified talc; lactose monohydrate; maize starch; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid; sucrose - gastro-oesophageal reflux disease (gord),? treatment of erosive reflux oesophagitis,? long-term management of patients with healed oesophagitis to prevent relapse,? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy,? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy.,? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy,? prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv (available in other brands) solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion,in combination with appropriate antibiotics for:,? healing of duodenal ulcer associated with helicobacter pylori,? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australia - English - Department of Health (Therapeutic Goods Administration)

torrent australasia pty ltd - esomeprazole magnesium, quantity: 20.706 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: copovidone; ethylcellulose; titanium dioxide; colloidal anhydrous silica; magnesium stearate; diethyl phthalate; light magnesium oxide; hypromellose; methacrylic acid - ethyl acrylate copolymer (1:1); purified talc; iron oxide red; crospovidone; sodium lauryl sulfate; silicified microcrystalline cellulose; povidone; macrogol 8000; polysorbate 80; lactose monohydrate; maize starch; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid; sucrose - gastro-oesophageal reflux disease (gord),? treatment of erosive reflux oesophagitis,? long-term management of patients with healed oesophagitis to prevent relapse,? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy,? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy.,? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy,? prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv (available in other brands) solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion,in combination with appropriate antibiotics for:,? healing of duodenal ulcer associated with helicobacter pylori,? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australia - English - Department of Health (Therapeutic Goods Administration)

torrent australasia pty ltd - esomeprazole magnesium, quantity: 20.706 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: macrogol 8000; copovidone; crospovidone; hypromellose; polysorbate 80; sodium lauryl sulfate; purified talc; silicified microcrystalline cellulose; ethylcellulose; colloidal anhydrous silica; magnesium stearate; light magnesium oxide; povidone; titanium dioxide; diethyl phthalate; iron oxide red; methacrylic acid - ethyl acrylate copolymer (1:1); lactose monohydrate; maize starch; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid; sucrose - gastro-oesophageal reflux disease (gord),? treatment of erosive reflux oesophagitis,? long-term management of patients with healed oesophagitis to prevent relapse,? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy,? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy.,? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy,? prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv (available in other brands) solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion,in combination with appropriate antibiotics for:,? healing of duodenal ulcer associated with helicobacter pylori,? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australia - English - Department of Health (Therapeutic Goods Administration)

torrent australasia pty ltd - esomeprazole magnesium, quantity: 20.706 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: polysorbate 80; copovidone; colloidal anhydrous silica; light magnesium oxide; crospovidone; diethyl phthalate; titanium dioxide; purified talc; sodium lauryl sulfate; silicified microcrystalline cellulose; methacrylic acid - ethyl acrylate copolymer (1:1); ethylcellulose; macrogol 8000; iron oxide red; magnesium stearate; hypromellose; povidone; lactose monohydrate; maize starch; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid; sucrose - gastro-oesophageal reflux disease (gord),? treatment of erosive reflux oesophagitis,? long-term management of patients with healed oesophagitis to prevent relapse,? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy,? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy.,? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy,? prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv (available in other brands) solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion,in combination with appropriate antibiotics for:,? healing of duodenal ulcer associated with helicobacter pylori,? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australia - English - Department of Health (Therapeutic Goods Administration)

torrent australasia pty ltd - esomeprazole magnesium, quantity: 20.706 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: light magnesium oxide; povidone; diethyl phthalate; sodium lauryl sulfate; titanium dioxide; iron oxide red; polysorbate 80; hypromellose; ethylcellulose; colloidal anhydrous silica; copovidone; methacrylic acid - ethyl acrylate copolymer (1:1); purified talc; crospovidone; magnesium stearate; macrogol 8000; silicified microcrystalline cellulose; lactose monohydrate; maize starch; sucrose; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - gastro-oesophageal reflux disease (gord),? treatment of erosive reflux oesophagitis,? long-term management of patients with healed oesophagitis to prevent relapse,? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy,? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy.,? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy,? prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv (available in other brands) solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion,in combination with appropriate antibiotics for:,? healing of duodenal ulcer associated with helicobacter pylori,? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australia - English - Department of Health (Therapeutic Goods Administration)

torrent australasia pty ltd - montelukast sodium, quantity: 10.4 mg (equivalent: montelukast, qty 10 mg) - tablet - excipient ingredients: magnesium stearate; microcrystalline cellulose; mannitol; croscarmellose sodium; aspartame; iron oxide yellow; iron oxide red; flavour - prophylaxis and treatment of chronic asthma in adults and children 2 years of age and older. symptomatic treatment of seasonal allergic rhinitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

torrent australasia pty ltd - montelukast sodium -

Australia - English - Department of Health (Therapeutic Goods Administration)

torrent australasia pty ltd - montelukast sodium, quantity: 5.2 mg (equivalent: montelukast, qty 5 mg) - tablet, chewable - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; magnesium stearate; mannitol; aspartame; iron oxide red; flavour - prophylaxis and treatment of chronic asthma in adults and children 2 years of age and older. symptomatic treatment of seasonal allergic rhinitis.